CLNN: Clene Inc. Stock

by  •  • Comments Off on CLNN: Clene Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 44.50
Enterprise Value ($M) 42.34
Book Value ($M) 13.39
Book Value / Share 0.10
Price / Book 3.32
NCAV ($M) -0.10
NCAV / Share -0.00
Price / NCAV -449.52

Profitability (mra)
Return on Invested Capital (ROIC) -1.09
Return on Assets (ROA) -1.24
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.53
Current Ratio 1.53

Balance Sheet (mrq) ($M)
Current Assets 38.85
Assets 52.34
Liabilities 38.95
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.65
Operating Income -40.54
Net Income -49.50

Cash Flow Statement (mra) ($M)
Cash From Operations -30.17
Cash from Investing -1.50
Cash from Financing 42.16

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G AWM Investment Company, Inc. 9.20
02-14 13G/A Citadel Advisors Llc 4.50
02-13 13G/A Vivo Opportunity Fund Holdings, L.P. 7.00 -29.53
06-20 13D/A Matlin David J 5.60 27.53

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 48,532 19,072 254.47
2024-04-25 91,506 19,631 466.13
2024-04-24 78,354 62,209 125.95
2024-04-23 73,103 27,205 268.71
2024-04-22 166,691 78,470 212.43

(click for more detail)

Similar Companies
CING – Cingulate Inc. CKPT – Checkpoint Therapeutics, Inc.
CLDX – Celldex Therapeutics, Inc. CLRB – Cellectar Biosciences, Inc.
CLVR – Clever Leaves Holdings Inc.


Financial data and stock pages provided by
Fintel.io